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INTRODUCTION

PET SCAN IMAGES

Human immunodeficiency virus (HIV) is associated with many
malignancies including non-Hodgkin Lymphoma, Kaposi sarcoma and
cervical cancer1. People with HIV have a risk ratio for AIDS-defining
malignancy of 14 compared to otherwise similar people without
1
HIV . The following case details a novel presentation of a rare HIVassociated malignancy (HIVAM), plasmablastic lymphoma.
CASE REPORT

A 29 y/o male presented to the hospital with diarrhea for one year
and new right upper quadrant abdominal pain associated with
hematochezia. A CT scan of the abdomen and pelvis revealed a
thickened cecal wall and prominent lymphadenopathy, suggestive of
malignancy or infection. HIV antibody was positive, with a viral load
of 1.3 million/ml. CD4 count of 51/cc. An RPR was positive, and a
treponemal antibody test confirmed the diagnosis of syphilis.
Cytomegalovirus PCR [of what] and stool studies for shigella toxin
were positive. Infectious colitis was suspected. Pertinent negatives
included Quantiferon Gold; PCR for Gonorrhea, Chlamydia, and
Pneumocystis jirovecii; and serology for Blastomyces, Histoplasma,
and Mycoplasma.
Therapy with pipracillin/tazobactam was initiated to treat syphilis and
shigellosis, along with ganciclovir for CMV. HIV was treated with a
highly active anti-retroviral (HAART) regimen of emtricitabinetenofovir, dolutegravir, ritonavir and darunavir. However, on day five
of HAART therapy, the patient developed sustained fevers to ~104 F.
HAART therapy was held while the patients was treated empirically
with azithromycin and ethambutol for Mycobacterial avium complex
infection unmasked by immune reconstitution.
During this period, the patient suddenly developed sustained
hypotension and profuse hematochezia. Hemorrhagic shock was
confirmed by a hemoglobin concentration of 5.6g/dL, down from
9.6g/dL twelve hours prior. He underwent fluid resuscitation and
then emergent laparotomy that revealed a hemorrhaging mass in
the cecum requiring hemicolecomy. Pathology of the mass was
diagnostic of plasmablastic lymphoma and a CT-PET scan showed
widespread metastases (Figure 1). Therapy with etoposide,
prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH)
was initiated. Six months later, a CT PET demonstrated nearly
complete remission (Figure 2) and the HIV viral load was
undetectable.
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DISCUSSION

HIVAM often manifests with indolent "B" symptoms, skin lesions, internal mass effects,
and less commonly acute symptoms such as, in the case of CNS lymphoma, seizures 2.
3
Plasmablastic lymphoma is a rare, aggressive, AIDS-defining illness . EPOCH remains
4
standard of care, though survival rates are poor . HAART is an essential component of
treatment that should be continued during chemotherapy because an undetectable viral
load is associated with increased survival5. This is the first report of plasmablastic
lymphoma presenting with hemorrhagic shock, and it illustrates that both the variety and
the clinical presentation of HIV-associated malignancies are broad.
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